证券代码：301321 证券简称：翰博高新 公告编号：2025-054 翰博高新材料（合肥）股份有限公司 关于部分董事、高级管理人员及特定股东减持股份的预披露公告 董事兼副总经理蔡姬妹女士及股东可传丽女士、许永壮先生保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 1、翰博高新材料（合肥）股份有限公司（以下简称"公司"或"转板公司"） 剔除公司回购专用账户中的股份数量后的总股本（以下简称"总股本"）为 173,835,406 股。 2、持有公司股份 303,750 股（占公司总股本比例 0.17%）的董事兼副总经 理蔡姬妹女士计划自本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方 式减持公司股份不超过 75,000 股（占公司总股本比例 0.04%）。 3、持有公司股份 101,250 股（占公司总股本比例 0.06%）的可传丽女士计 划自本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减持公司股份 不超过 101,250 股（占公司总股本比例 0.06%）。 4、持有 ...

Core Viewpoint - The innovative drug sector has rebounded strongly since September, driven by the upcoming 2025 National Negotiation, with significant trading activity observed in the Hang Seng Innovative Drug ETF (520500) on the first trading day of November [1]. Group 1: Market Activity - The Hang Seng Innovative Drug ETF (520500) recorded a half-day trading volume of 1.105 billion yuan on November 1, 2025, indicating active market participation [1]. - The ETF's trading volume has increased significantly, with total trading amounts of 604 million yuan and 1.654 billion yuan on October 30 and 31, respectively, compared to an average daily trading volume of 584 million yuan since October [1]. Group 2: Policy Developments - The 2025 National Medical Insurance Directory negotiations commenced on October 30, 2025, introducing a commercial health insurance innovative drug directory, marking a shift from a "basic insurance only" model to a "medical insurance + commercial insurance" collaborative payment approach [1]. - A total of 535 drug generic names were approved for the basic drug directory, while 121 were approved for the commercial insurance innovative drug directory, with 79 names submitted for both directories [1]. Group 3: Industry Outlook - The establishment of the commercial insurance innovative drug directory is expected to diversify payment methods, particularly benefiting high-value innovative drugs and multinational pharmaceutical products, potentially opening up new growth opportunities for the industry [1]. - The Hang Seng Innovative Drug ETF (520500) is designed to track companies involved in innovative drug research, development, and production, focusing on firms with strong R&D capabilities [1]. - As of October 31, 2025, the top five constituents of the index include BeiGene, China Biologic Products, Innovent Biologics, Kelun-Biotech, and CanSino Biologics, reflecting the index's focus on high-potential companies in the innovative drug sector [1].

证券代码：301321 证券简称：翰博高新 公告编号：2025-053 翰博高新材料（合肥）股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 为保证子公司的正常生产经营活动，根据未来的融资和担保需求，翰博高 新材料（合肥）股份有限公司（以下简称"公司"）分别于 2024 年 12 月 13 日 召开第四届董事会第十四次会议、第四届监事会第十二次会议，于 2024 年 12 月 31 日召开 2024 年第三次临时股东大会，审议通过《关于预计公司 2025 年度 为子公司提供担保额度的议案》，同意公司 2025 年为合并报表范围内子公司提 供担保，新增总担保额度不超过人民币 224,800 万元，担保用途分为融资性担 保和非融资性担保，融资性担保主要用于控股子公司在银行及其他金融机构的 授信融资业务（授信融资品种及用途包括但不限于：流动资金贷款、项目贷款、 保函、信用证、银行承兑汇票、保理、押汇、外汇及金融衍生品等业务）提供 担保，非融资性担保主要用于为控股子公司在对应债权人处购买产品提供担保 等 ...

证券代码：301321 证券简称：翰博高新 公告编号：2025-052 翰博高新材料（合肥）股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | | | | | | | 占公 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 持股数量 | 持股比 | 本次质押前 | 本次质押后 | 占其所 | 司总 | 已质押股 | 占已 质押 | 未质押 | 占未 | | 股东 | | | 质押股份数 | 质押股份数 | 持股份 | 股本 | 份限售和 | | 股份限 | 质押 | | 名称 | （股） | 例(%) | 量（股） | 量（股） | 比例(%) | 比例 | 冻结、标记 | 股份 | 售和冻 | 股份 | | | | | | | | (%) | 数量（股） | 比例 | 结数量 | 比例 | | | | | | | | | | (%) | （股） | (%) | | 王照 ...

Core Insights - Hanbo High-tech (301321.SZ) released its Q3 2025 report on October 27, 2025, indicating a total of 5 institutional investors holding shares, amounting to 45.81 million shares, which represents 24.57% of the total share capital [1] Institutional Holdings - The total institutional holding increased by 0.18 percentage points compared to the previous quarter [1] - The institutional investors include Hanbo Holdings Group Co., Ltd., Hefei Wang's Hanbo Technology Co., Ltd., Changjiang Wealth Asset Management, Hanbo High-tech Materials (Hefei) Co., Ltd., and Industrial and Commercial Bank of China [1] Public Fund Activity - One new public fund disclosed this quarter, namely the Dacheng CSI 360 Internet + Index A [1] - A total of 38 public funds were not disclosed this quarter compared to the previous quarter, including funds like Guojin Quantitative Multi-Factor A and Huatai-PineBridge CSI 2000 Index Enhanced A [1]

Market Performance - The main board saw significant gains with notable stocks such as Dahua Intelligent (+10.12%), Fangzheng Technology (+10.05%), and Huanxu Electronics (+10.02%) [1] - The ChiNext board led the gains with Kexiang Co. (+20.00%) and Xiangnong Chip (+20.00%) [1] - The Sci-Tech Innovation board also performed well, with Purang Co. (+20.00%) and Shengyi Electronics (+19.99%) [1] - Active sub-industries included SW Communication Network Equipment and Devices (+7.49%) and SW Printed Circuit Boards (+7.06%) [1] Domestic News - Aibang ARAI glasses announced that Lipai Optics completed a new round of financing to enhance the industrialization of AR geometric waveguides [1] - Maxke Electronics signed a strategic cooperation agreement in Zhengzhou for a large silicon wafer project with a total investment of approximately 7 billion yuan [1] - Xiaomi's president responded to pricing issues for the new Redmi K90 series, citing significant increases in memory chip prices affecting manufacturing costs [1] - Lian Micro announced that its 6-inch silicon carbide-based gallium nitride products have passed customer validation and are expected to ship in Q4 2025 [1] Company Announcements - Hand Information reported a revenue of 2.439 billion yuan for the first three quarters of 2025, a year-on-year increase of 3.67%, with a net profit of 145 million yuan, up 6.96% [3] - Hanbo High-tech reported a revenue of 870 million yuan for Q3 2025, a year-on-year increase of 33.34%, with a net profit of 17.66 million yuan, up 153.33% [3] - Kelik reported a revenue of 4.105 billion yuan for the first three quarters of 2025, a year-on-year increase of 24.86%, with a net profit of 232 million yuan, up 52.51% [3] - Jiechuang Intelligent reported a revenue of 599 million yuan for the first three quarters of 2025, a year-on-year increase of 30.73%, with a net profit of 22.77 million yuan, turning from loss to profit [3] International News - Elon Musk announced that Samsung Electronics will participate in the production of Tesla's AI chip "AI5," indicating a shift in production dynamics [2] - TSMC's Japanese subsidiary JASM signed a contract for a new factory in Kumamoto, expected to start operations by the end of 2027, focusing on 6nm process semiconductors [2] - ASML delivered its first lithography machine designed for advanced packaging applications, aimed at addressing the complexities of chip packaging [2] - Google announced a deal with Anthropic to supply up to 1 million AI chips and additional cloud services, valued at several billion dollars [2]

Core Viewpoint - Hanbo High-tech (301321.SZ) reported significant growth in its Q3 2025 financial results, indicating strong operational performance and recovery from previous losses [1] Financial Performance - In Q3 2025, the company achieved operating revenue of 870 million yuan, representing a year-on-year increase of 33.34% [1] - The net profit for Q3 2025 was 17.66 million yuan, showing a substantial year-on-year growth of 153.33% [1] - For the first three quarters of 2025, the company recorded total operating revenue of 2.424 billion yuan, which is a year-on-year growth of 44.06% [1] - However, the company reported a net loss of 8.79 million yuan for the first three quarters of 2025 [1]

Core Insights - The company reported a revenue of 2.424 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 44.06% [1] - The net loss attributable to shareholders of the listed company was 8.7869 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 28.0801 million yuan [1] - The basic loss per share was 0.0501 yuan [1]

Group 1 - The company Hanbo High-tech (SZ 301321) held its 24th meeting of the 4th board of directors on October 24, 2025, in Hefei, Anhui Province, to discuss the reappointment of the auditing firm for the 2025 fiscal year [1] - For the fiscal year 2024, Hanbo High-tech's revenue composition is 95.24% from the backlight display module industry and 4.76% from other businesses [1] - As of the report date, Hanbo High-tech has a market capitalization of 3.2 billion yuan [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示：本次公司续聘会计师事务所符合财政部、国务院国资委、中国证 监会印发的《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕 4 号）的规定。 翰博高新材料（合肥）股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第四届董事会第二十一次会议，审议通过了《关于续聘公司 2025 年度审计机构的议案》，拟续聘容诚会计师事务所（特殊普通合伙）（以下简称 "容诚会计师事务所"）为公司 2025 年度财务报告及内部控制的审计机构，本 事项尚需提交股东会审议，现将相关情况公告如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 证券代码：301321 证券简称：翰博高新 公告编号：2025-050 翰博高新材料（合肥）股份有限公司 关于续聘公司 2025 年度审计机构的公告 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证 ...